Psyrex is developing a treatment that will shorten the treatment time for depression

Treatment-resistant depression (TRD) is currently considered one of the significant challenges of psychiatry: millions of patients who do not respond satisfactorily to the existing medications, alongside heavy costs for the health care systems and a permanent loss of function.

Psirex’s technology is based on a combination of a known antidepressant from the SSRI family with ibogaine – a psychoactive substance with a unique pharmacological profile, given in a precise and controlled dose. The combination was built to focus the biological effect without relying on conscious experience, as part of a pharmaceutical approach adapted to a full regulatory pathway. The company emphasizes that the development was done in advance according to the standards of the pharmaceutical industry, and not as an experimental or alternative therapeutic solution.

Grotto places the move in a broader perspective: “Depression is not just an individual clinical challenge, but a wide-ranging phenomenon with the characteristics of a silent epidemic. The impact is evident on life expectancy, daily functioning and the economy. Solutions are required that understand the medical urgency, but also meet strict scientific and regulatory standards.”

Psyrex, which operates as a public company, is currently in advanced stages of development towards the first clinical trials in humans. The company’s current capital raising is intended to enable progress to clinical and regulatory value intersections – a critical step for early-stage pharma companies.